molecules of the month

IOA-244 (roginolisib)

oral QD non-competitive PI3Kd inhibitor

Ph. I in metastatic cancers

from focused kinase inhibitor screen
(60K cmpds) + opt.

Cancer Res. Commun., April 14, 2023

Merck Serono / iOnctura, CH

IOA-244, PI3Kd, oral QD non-competitive PI3Kd inhibitor, Ph. I in metastatic cancers, from focused kinase inhibitor screen (60K cmpds) + opt., Cancer Res. Commun., April 14, 2023 MERCK SERONO / IONCTURA, CH
8 mins read

The first non-ATP-competitive inhibitor of the long-pursued PI3Kδ kinase. Phosphatidylinositol-3-kinase (PI3K) has received intense attention as a drug target from the pharmaceutical industry due to its central role in cancer and involvement in other indications. As described in our recent overview of this area, numerous compounds have entered clinical trials for this target, and six PI3K inhibitors have been approved (five in cancers). However, a number of these drugs have exhibited significant toxicity issues, resulting in black box warnings and subsequent partial or full withdrawals due to safety concerns. Roginolisib (IOA-244) is the first non-ATP-competitive PI3Kδ inhibitor whose novel chemotype may help assess whether different human safety profiles may be achievable with PI3Kδ inhibition. PI3Kδ isoform-selectivity achieved with ATP-competitive inhibitors…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: